Table 6.
Comparison of the percentages of MK, MK + MKA and total monacolins per pill to monacolin labelling; amounts of MK, MK + MKA and total monacolins per recommended daily serving.
| N° | Amount of Monacolin(s) Claimed Per Pill (mg) 1 | % Measured/Claimed Per Pill | Serving(s) Per Day 4 | MK Amount (mg/day) 5 |
MK + MKA Amount (mg/day) 5 |
Total Monacolins (mg/day) 5 |
||||
|---|---|---|---|---|---|---|---|---|---|---|
| MK 2 | MK + MKA 2 | Total Monacolins 3 | UHPLC 3 | NMR 3 | ||||||
| UHPLC | NMR | |||||||||
| 1 | MK 2.6 | 51 | 70 | 71 | 65 | 1 | 1.3 | 1.8 | 1.8 | 1.7 |
| 2 | MK + MKA 10.05 | 68 | 76 | 88 | 91 | 1 | 6.8 | 7.6 | 8.8 | 9.2 |
| 3 | MK 2.8 | 77 | 85 | 94 | 110 | 3 | 6.5 | 7.2 | 7.9 | 9.2 |
| 4 | M. purpureus 1.0 6 | 48 | 58 | 109 | 99 | 3 | 1.4 | 1.7 | 3.3 | 3.0 |
| 5 | 1 | 1.8 | 2.3 | 3.0 | 2.5 | |||||
| 6 | MK 3.33 | 62 | 71 | 87 | 83 | 3 | 6.2 | 7.1 | 8.7 | 8.3 |
| 7 | 1 | 2.2 | 2.6 | 4.1 | 3.8 | |||||
| 8 | 2 | 12.5 | 16.8 | 19.7 | 17.5 | |||||
| 9 | 2 | 8.3 | 8.6 | 9.2 | 10.3 | |||||
| 10 | MK 9 | 9 | 20 | 26 | 23 | 4 | 3.4 | 7.2 | 9.3 | 8.3 |
| 11 | MK 2.6 | 3 | 3 | 3 | 4 | 0.3 | 0.3 | 0.3 | ||
| 12 | MK 2.6 | 3 | 3 | 3 | 1 | 0.08 | 0.08 | 0.08 | ||
| 13 | MK 24.0 | 97 | 99 | 99 | 100 | 2 | 46.2 | 47.6 | 47.7 | 47.8 |
| 14 | 2 | 4.4 | 4.9 | 7.5 | 6.7 | |||||
| 15 | MK 9.6 | 86 | 100 | 146 | 126 | 1 | 8.3 | 9.6 | 14.0 | 12.1 |
| 16 | 2 | 0.7 | 0.7 | 0.8 | 0.6 | |||||
| 17 | 2–3 | 2.2–3.3 | 2.5–3.8 | 3.7–5.6 | 3.0–4.5 | |||||
| 18 | 1 | 6.4 | 7.4 | 7.9 | 8.5 | |||||
| 19 | 2–4 | 0.5–1.0 | 0.6–1.2 | 1.0–2.0 | 0.8–1.6 | |||||
| 20 | MK 2.6 | 50 | 68 | 69 | 68 | 1 | 1.8 | 1.8 | 1.8 | 1.7 |
| 21 | 2–4 | 0.5–1.0 | 0.6–1.2 | 1.0–2.0 | 0.95–1.9 | |||||
| 22 | MK 2.33 | 76 | 105 | 134 | 131 | 3 | 5.3 | 7.4 | 9.4 | 9.2 |
| 23 | MK 9 | 94 | 102 | 109 | 118 | 1 | 8.5 | 9.2 | 9.8 | 10.6 |
| 24 | MK 10.0 | 52 | 107 | 108 | 117 | 1 | 5.2 | 10.7 | 10.8 | 11.7 |
| 25 | Monacolin 9.6 | 59 | 96 | 118 | 103 | 1 | 5.7 | 9.3 | 11.3 | 9.9 |
| 26 | MK 5.0 | 70 | 78 | 95 | 91 | 1–2 | 3.5–7.0 | 3.9–7.8 | 4.8–9.5 | 4.5–9.1 |
| 27 | MK 2.6 | 103 | 126 | 130 | 153 | 1 | 2.7 | 3.3 | 3.4 | 4.0 |
| 28 | 1 | 1.0 | 1.4 | 2.1 | 1.7 | |||||
| 29 | 2–4 | 0.2–0.3 | 0.2–0.4 | 0.25–0.5 | ||||||
| 30 | Monacolin 3.3 | 66 | 77 | 93 | 91 | 3 | 6.6 | 7.7 | 9.3 | 9.0 |
| 31 | 1 | 0.9 | 1.2 | 1.4 | 1.2 | |||||
1 The exact monacolin labelling is indicated for each formulation. 2 Percentages of MK and MK + MKA were calculated from amounts determined by UHPLC-DAD-MS (see Table 5). 3 Percentages of total monacolins determined by UHPLC-DAD-MS and 1H-NMR correspond, respectively, to TotalM and TotalM-DiMK (see Table 3 and Table 5). 4 Serving(s) recommended per day on the label. 5 Amounts of MK, MK + MKA and total monacolins per recommended daily serving. 6 The exact label is: 750 mg of organic RYR titrated at 0.4% of Monascus purpureus for three pills.